Description
Brentuximab vedotin: an innovative treatment for patients with Hodgkin and systemic anaplastic large cell lymphoma
Article: Brentuximab vedotin: an innovative treatment for patients with Hodgkin and systemic anaplastic large cell lymphoma
€3.03
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Highlights in digestive oncology
€3.03 Add to cart -
Article: Highlights in digestive oncology
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart
